WO2003040369A3 - Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments - Google Patents
Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments Download PDFInfo
- Publication number
- WO2003040369A3 WO2003040369A3 PCT/IB2002/004219 IB0204219W WO03040369A3 WO 2003040369 A3 WO2003040369 A3 WO 2003040369A3 IB 0204219 W IB0204219 W IB 0204219W WO 03040369 A3 WO03040369 A3 WO 03040369A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tumoral
- reversion
- apoptosis
- suppression
- medicines
- Prior art date
Links
- 230000001173 tumoral effect Effects 0.000 title abstract 4
- 206010034133 Pathogen resistance Diseases 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- 230000001629 suppression Effects 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012472 biological sample Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003990 molecular pathway Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention concerne notamment de nouvelles séquences impliquées dans les voies moléculaires de 1a suppression tumorale, la réversion tumorale, l'apoptose et/ou 1a résistance aux virus. Elle concerne également l'utilisation de ces sequences ou le traitement contre le cancer, maladies virales, maladies neurodégénératives ainsi qu'en matière de diagnostique ainsi que pour 1a mise en oeuvre de procédés de criblage de composés à tester. Cette invention a également pour objet des procédés de détection et/ou de dosage des sequences de l'invention ou de leurs produits d'expression dans un prélèvement biologique
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR01/11981 | 2001-09-17 | ||
FR0111981 | 2001-09-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003040369A2 WO2003040369A2 (fr) | 2003-05-15 |
WO2003040369A3 true WO2003040369A3 (fr) | 2004-07-29 |
Family
ID=8867345
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/004219 WO2003040369A2 (fr) | 2001-09-17 | 2002-09-17 | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2003040369A2 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003087372A2 (fr) * | 2002-04-12 | 2003-10-23 | Molecular Engines Laboratories | Facteur de croissance derive d’hepatome et son utilisation |
US8163482B2 (en) | 2006-02-23 | 2012-04-24 | Nicholas Katsanis | BBS10 related diagnostic methods for Bardet-Biedl syndrome |
MY154507A (en) | 2012-03-19 | 2015-06-22 | Malaysian Palm Oil Board | Gene Controlling Shell Phenotype in Palm |
MY156871A (en) * | 2013-07-18 | 2016-04-07 | Malaysian Palm Oil Board | Detection methods for oil palm shell alleles |
NO344051B1 (en) * | 2017-05-04 | 2019-08-26 | Patogen As | Novel virus in Fish and Method for detection |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017434A2 (fr) * | 1995-11-09 | 1997-05-15 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Utilisation de la lecithine-cholesterol acyltransferase (lcat) dans le traitement de l'atherosclerose |
WO1997022695A2 (fr) * | 1995-12-20 | 1997-06-26 | Fondation Jean Dausset-Ceph | Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer |
WO2000008147A1 (fr) * | 1998-08-05 | 2000-02-17 | Molecular Engines Laboratories | Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus |
WO2001051670A2 (fr) * | 2000-01-07 | 2001-07-19 | Curagen Corporation | Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe |
WO2001057182A2 (fr) * | 2000-01-31 | 2001-08-09 | Human Genome Sciences, Inc. | Acides nucleiques, proteines et anticorps |
WO2001059063A2 (fr) * | 2000-01-31 | 2001-08-16 | Human Genome Sciences, Inc. | Acides nucleiques, proteines et anticorps |
-
2002
- 2002-09-17 WO PCT/IB2002/004219 patent/WO2003040369A2/fr not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997017434A2 (fr) * | 1995-11-09 | 1997-05-15 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Utilisation de la lecithine-cholesterol acyltransferase (lcat) dans le traitement de l'atherosclerose |
WO1997022695A2 (fr) * | 1995-12-20 | 1997-06-26 | Fondation Jean Dausset-Ceph | Sequences nucleotidiques, proteines, medicaments et agents diagnostiques utiles dans le traitement du cancer |
WO2000008147A1 (fr) * | 1998-08-05 | 2000-02-17 | Molecular Engines Laboratories | Genes impliques dans les voies moleculaires de la suppression tumorale et/ou la resistance aux virus |
WO2001051670A2 (fr) * | 2000-01-07 | 2001-07-19 | Curagen Corporation | Acides nucleiques renfermant des polymorphismes de nucleotide simple et procede d'utilisation associe |
WO2001057182A2 (fr) * | 2000-01-31 | 2001-08-09 | Human Genome Sciences, Inc. | Acides nucleiques, proteines et anticorps |
WO2001059063A2 (fr) * | 2000-01-31 | 2001-08-16 | Human Genome Sciences, Inc. | Acides nucleiques, proteines et anticorps |
Non-Patent Citations (6)
Title |
---|
BRENNER SYDNEY ET AL: "Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays.", NATURE BIOTECHNOLOGY, vol. 18, no. 6, June 2000 (2000-06-01), pages 630 - 634, XP002199492, ISSN: 1087-0156 * |
DATABASE GSN [online] 23 January 2002 (2002-01-23), XP002237861, Database accession no. ABA16909 * |
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237857, Database accession no. AAK83051 * |
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237858, Database accession no. AAK87567 * |
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237859, Database accession no. AAK83993 * |
DATABASE GSN [online] 7 November 2001 (2001-11-07), XP002237860, Database accession no. AAK82571 * |
Also Published As
Publication number | Publication date |
---|---|
WO2003040369A2 (fr) | 2003-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004067570A3 (fr) | Diagnostic et traitement du cancer de la prostate | |
TW200736253A (en) | Pyridopyrazine derivatives and their use | |
WO2006127861A3 (fr) | Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides | |
WO2004066941A3 (fr) | Profils d'expression destines au cancer du colon et procedes d'utilisation | |
WO2009090553A3 (fr) | Compositions et procédés de détection de peptides post-arrêts | |
WO2005084109A3 (fr) | Gène mh15 spécifique de cancer | |
WO2004089951A8 (fr) | Derives d’imidazo-pyridine ayant une affinite sur des recepteurs de la melanocortine | |
WO2007141280A3 (fr) | protéines | |
WO2005059108A3 (fr) | Profils d'expression geniques et procedes d'utilisation | |
WO2008073177A3 (fr) | Profils d'expression génique et protéique associés à l'efficacité thérapeutique de l'irinotécan | |
WO2009019370A3 (fr) | Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal | |
WO2004078035A3 (fr) | Profiles d'expression pour le cancer du sein et methodes d'utilisation | |
WO2004046332A3 (fr) | Genes amplifies impliques dans un cancer | |
WO2005005661A3 (fr) | Genes regules dans le cancer de l'ovaire utilises comme cibles pronostique et therapeutique | |
WO2001071357A3 (fr) | Proteines, genes et leur utilisation pour diagnostiquer et traiter le cancer de la poitrine | |
WO2003040369A3 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
WO2007071829A3 (fr) | Méthodes et moyens relatifs à des maladies | |
WO2002064731A3 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale reversion tumorale apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
EP2209000A3 (fr) | Detection, suivit et traitement de cancer | |
WO2003025176A8 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
WO2003025175A3 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
WO2003004526A3 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
WO2008026008A8 (fr) | Protéine | |
WO2003025177A3 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments | |
WO2002059256A3 (fr) | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |